Vericiguat Drug Analysis Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: vericiguat" drug pipelines has been added to ResearchAndMarkets.com's offering.

Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway. In heart failure, there is reduced bioavailability of nitric oxide due to systemic inflammation and vascular dysfunction, resulting in a reduction in cGMP synthesis. Disruption in the nitric oxide-sGC-cGMP pathway results in issues in the regulation of myocardial and renal function, thus resulting in increased potential for myocardial damage.

Product Profiles

List of Figures

Figure 1: Vericiguat for chronic heart failure - SWOT analysis

Figure 2: Drug assessment summary of vericiguat for chronic heart failure

Figure 3: Drug assessment summary of vericiguat for chronic heart failure

Figure 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Vericiguat drug profile

Table 2: Vericiguat Phase III trials in chronic heart failure

Table 3: Vericiguat Phase II data in chronic heart failure

Table 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qqj67v/vericiguat_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs